Alemtuzumab
- Generic Name
- Alemtuzumab
- Brand Names
- Campath, Lemtrada, MabCampath
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 216503-57-0
- Unique Ingredient Identifier
- 3A189DH42V
- Background
Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regio...
- Indication
用于烷化剂氟达拉滨（fludarabine）治疗失败的B细胞性慢性淋巴细胞白血病患者；亦可用于复发缓解型多发性硬化症治疗。
- Associated Conditions
- B-Cell Chronic Lymphocytic Leukemia, Kidney Transplant Rejection, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Steroid Refractory Acute Graft Versus Host Disease, T-cell Prolymphocytic Leukemia (T-PLL), Refractory Autoimmune Hemolytic Anemia, Refractory Idiopathic thrombocytopenic purpura
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma
- First Posted Date
- 2013-03-07
- Last Posted Date
- 2013-03-07
- Lead Sponsor
- University of Göttingen
- Target Recruit Count
- 41
- Registration Number
- NCT01806337
Belatacept Early Steroid Withdrawal Trial
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 316
- Registration Number
- NCT01729494
- Locations
- 🇺🇸
University of Wisconsin-Madison, Madison, Wisconsin, United States
🇺🇸Tampa General Hospital, Tampa, Florida, United States
🇺🇸The Christ Hospital, Cincinnati, Ohio, United States
Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2019-04-30
- Target Recruit Count
- 40
- Registration Number
- NCT01712945
- Locations
- 🇬🇧
Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom
High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment
- Conditions
- Interventions
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Seah Lim M.D.
- Target Recruit Count
- 1
- Registration Number
- NCT01679041
- Locations
- 🇺🇸
Texas Oncology, Amarillo, Texas, United States
🇺🇸Dr Ruby Saulog, Amarillo, Texas, United States
🇺🇸Amarillo Diagnostic Clinic, Amarillo, Texas, United States
Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis
- Conditions
- First Posted Date
- 2012-07-12
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Children's Hospital Los Angeles
- Registration Number
- NCT01639573
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT01625351
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2014-03-11
- Lead Sponsor
- Samuel Forrester Hunter, MD, PhD
- Target Recruit Count
- 60
- Registration Number
- NCT01624714
- Locations
- 🇺🇸
Advanced Neurosciences Institute, Franklin, Tennessee, United States
Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
- First Posted Date
- 2012-05-11
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 16
- Registration Number
- NCT01596699
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT01518153
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)
- Conditions
- Interventions
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 45
- Registration Number
- NCT01499888
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.